MDXG:NSD-MiMedx Group, Inc (USD)

COMMON STOCK | Medical Devices | NSD

Last Closing Price

USD 12.55

Change

+0.35 (+2.87)%

Market Cap

USD 1.37B

Volume

0.40M

Avg Analyst Target

USD 20.00 (+59.36%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, pressure ulcers, and burns; AmnioFix, a semi-permeable protective barrier membrane product for the treatment of wounds related to surgical procedures; EpiCord and AmnioCord that are dehydrated human umbilical cord allografts intended for homologous applications; and AmnioFill that consists of particles of connective tissue matrix derived from placental disc and placental membranes. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. is headquartered in Marietta, Georgia.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-08-03 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ALGN Align Technology, Inc

+1.34 (+0.19%)

USD55.06B 79.31 59.42
PODD Insulet Corporation

+0.16 (+0.06%)

USD19.16B 2,202.28 159.45
ABMD Abiomed, Inc

-1.84 (-0.56%)

USD14.83B 66.22 55.76
LVGO Livongo Health, Inc

N/A

USD14.20B N/A N/A
BRKR Bruker Corporation

-1.72 (-2.08%)

USD12.46B 62.26 31.59
TNDM Tandem Diabetes Care, Inc

-1.63 (-1.53%)

USD6.81B N/A N/A
SWAV ShockWave Medical, Inc

+0.21 (+0.12%)

USD6.37B N/A N/A
IART Integra LifeSciences Holdings ..

-0.37 (-0.52%)

USD6.12B 30.06 26.83
INMD InMode Ltd

+0.38 (+0.33%)

USD4.34B 38.00 31.47
LIVN LivaNova PLC

-4.39 (-5.00%)

USD4.23B 77.40 N/A

ETFs Containing MDXG

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 38.22% 66% D 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 38.22% 66% D 82% B-
Trailing 12 Months  
Capital Gain 134.58% 82% B- 89% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 134.58% 82% B- 89% B+
Trailing 5 Years  
Capital Gain 63.41% 63% D 59% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 63.41% 63% D 55% F
Average Annual (5 Year Horizon)  
Capital Gain 27.53% 58% F 74% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 27.53% 56% F 73% C
Risk Return Profile  
Volatility (Standard Deviation) 93.35% 33% F 17% F
Risk Adjusted Return 29.49% 45% F 46% F
Market Capitalization 1.37B 76% C 70% C-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 13.31 49% F 60% D-
Price/Book Ratio 84.73 1% F 1% F
Price / Cash Flow Ratio -45.26 81% B- 86% B
EV/EBITDA 117.93 30% F 9% F
Management Effectiveness  
Return on Equity -92.45% 29% F 20% F
Return on Invested Capital -43.51% 33% F 18% F
Return on Assets -13.40% 44% F 24% F
Debt to Equity Ratio -31,798.00% 100% A+ 100% A+
Technical Ratios  
Short Ratio 5.37 33% F 23% F
Short Percent 8.21% 24% F 24% F
Beta 1.62 30% F 24% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector